Beta3_LVH is an investigator-initiated project lead by Prof. J.L. Balligand (IREC, UCL) funded by a European Union’s Horizon 2020 research and innovation program (grant agreement N° 634559).
As part of ECRIN (European Clinical Research Infrastructure network), the CIEC has performed the regulatory and ethics submissions of the Beta3_LVH study in Belgium and will be in charge of the on-site monitoring activities of the site Cliniques universitaires Saint-Luc in Brussels. With the study initiation end of April 2016, an important project milestone has been achieved.
The objective of this project is to prevent patients having a structural heart remodelling and therefore at risk, to develop a heart failure. 12 partners in 8 european countries participate to the Beta3_LVH project.
The project is a clinical trial with an already marketed drug, known to be effective in bladder disorders, that will be administered to patients in a new indication on top of a standard treatment.
The patients suffering from a structural and functional defect of the left ventricle are targeted. Their cardiac hypertrophy and left ventricle function will be monitored through the whole study to assess the possible benefit of the tested medication.
In addition, the effect of the drug will be also measured on endothelial function and on the abundance/activity of beige/brown fat. Indeed, the medication can also have an influence on the endothelium which could have a positive effect on the cardiac remodelling and on the beige/brown fat that may influence peripheral and cardiac metabolism.
Additional information on this trial are available on the following websites:
https://clinicaltrials.gov/ct2/show/NCT02599480
Study details: www.luxclin.lu/Studies/Details/?c=STP8012FFS
.jpg)
.jpg)
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
